紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效观察
目的：探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性。方法：选取2011年2月—2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90例,以随机数字表法分为观察组和对照组,每组45例。对照组患者给予紫杉醇联合顺铂,观察组患者给予紫杉醇联合奥沙利铂。观察两组患者的临床疗效、5年生存情况和不良反应发生情况。结果：观察组、对照组患者的总有效率分别为95.56%（43/45）、93.33（42/45）,5年生存率分别为88.89%（40/45）、86.67%（39/45）,两组的差异均无统计学意义（P〉0.05）。观察组患者不良反应发生率为4.44%（2/45）,明显低...
Saved in:
| Published in | 中国医院用药评价与分析 Vol. 17; no. 8; pp. 1061 - 1062 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
福建医科大学附属龙岩第一医院妇科,福建龙岩,364000%龙岩市第二医院肿瘤科,福建龙岩,364000
2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-2124 |
| DOI | 10.14009/j.issn.1672-2124.2017.08.021 |
Cover
| Abstract | 目的：探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性。方法：选取2011年2月—2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90例,以随机数字表法分为观察组和对照组,每组45例。对照组患者给予紫杉醇联合顺铂,观察组患者给予紫杉醇联合奥沙利铂。观察两组患者的临床疗效、5年生存情况和不良反应发生情况。结果：观察组、对照组患者的总有效率分别为95.56%（43/45）、93.33（42/45）,5年生存率分别为88.89%（40/45）、86.67%（39/45）,两组的差异均无统计学意义（P〉0.05）。观察组患者不良反应发生率为4.44%（2/45）,明显低于对照组的20.00%（9/45）,差异有统计学意义（P〈0.05）。结论：紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效较好,不良反应少,安全性高。 |
|---|---|
| AbstractList | 目的：探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性。方法：选取2011年2月—2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90例,以随机数字表法分为观察组和对照组,每组45例。对照组患者给予紫杉醇联合顺铂,观察组患者给予紫杉醇联合奥沙利铂。观察两组患者的临床疗效、5年生存情况和不良反应发生情况。结果：观察组、对照组患者的总有效率分别为95.56%（43/45）、93.33（42/45）,5年生存率分别为88.89%（40/45）、86.67%（39/45）,两组的差异均无统计学意义（P〉0.05）。观察组患者不良反应发生率为4.44%（2/45）,明显低于对照组的20.00%（9/45）,差异有统计学意义（P〈0.05）。结论：紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效较好,不良反应少,安全性高。 R979.1; 目的:探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性.方法:选取2011年2月-2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90例,以随机数字表法分为观察组和对照组,每组45例.对照组患者给予紫杉醇联合顺铂,观察组患者给予紫杉醇联合奥沙利铂.观察两组患者的临床疗效、5年生存情况和不良反应发生情况.结果:观察组、对照组患者的总有效率分别为95.56％ (43/45)、93.33(42/45),5年生存率分别为88.89％ (40/45)、86.67％(39/45),两组的差异均无统计学意义(P＞0.05).观察组患者不良反应发生率为4.44％ (2/45),明显低于对照组的20.00％(9/45),差异有统计学意义(P＜0.05).结论:紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效较好,不良反应少,安全性高. |
| Abstract_FL | OBJECTIVE:To probe into the efficacy and safety of paclitaxel combined with oxaliplatin in treatment of advanced and recurrent cervical cancer.METHODS:90 patients with advanced and recurrent cervical cancer admitted into Longyan the First Hospital Affiliated to Fujian Medical University from Feb.2011 to Mar.2012 were selected to be divided into observation group and control group via the random number table,with 45 cases in each.The control group was treated with paclitaxel combined with cisplatin,while the observation group received paclitaxel combined with oxaliplatin.The clinical efficacy,5-year survival and incidence of adverse drug reactions of two groups were observed.RESULTS:The total effective rate of observation group and control group were respectively 95.56％ (43/45) and 93.33 (42/45),yet the 5-year survival rate were respectively 88.89％ (40/45) and 86.67％ (39/45),without any statistical significance between two groups (P ＞ 0.05).The incidence of adverse drug reactions of observation group was 4.44％ (2/45),significantly lower than that of control group 20.00％ (9/45),with statistically significant difference (P ＜ 0.05).CONCLUSIONS:The efficacy of paclitaxel combined with oxaliplatin in treatment of advanced and recurrent cervical cancer is significant with few adverse drug reactions and high safety. |
| Author | 陈福春 钟莉 |
| AuthorAffiliation | 福建医科大学附属龙岩第一医院妇科,福建龙岩364000 龙岩市第二医院肿瘤科,福建龙岩364000 |
| AuthorAffiliation_xml | – name: 福建医科大学附属龙岩第一医院妇科,福建龙岩,364000%龙岩市第二医院肿瘤科,福建龙岩,364000 |
| Author_FL | CHEN Fuchun ZHONG Li |
| Author_FL_xml | – sequence: 1 fullname: CHEN Fuchun – sequence: 2 fullname: ZHONG Li |
| Author_xml | – sequence: 1 fullname: 陈福春 钟莉 |
| BookMark | eNo9kEtLw0AUhWdRwVr7JwR3Js7cmTy6lOILC266L9NkpqZoWhtE60pL0Qg-8UWLUhBLkYJCcSH4d0zS_gtTKt7Nhct37uGcGZRwK65AaJ5glTCMM4tl1fE8VyW6AQoQYCpgYqjYVDGQBEr-36dR2vOcIgbNwACUJdFG9NkPn89GJ6fD47vg2g-63XDQCvy30W0jHHxHD49hqx0-dX6-LoPXi-DqJjzqBe_90Ysftc6jdnMM3PvDXiP46MyiKcm3PZH-2ymUX1nOZ9eU3ObqenYpp1g6I4oAXdqYcdNihHKgtmmJImjcBhAUmAlcSqExTC3CbQ1jofGMVrR1SxImLaLTFFqYvN3nruRuqVCu7NXc2LBwWKrHUy3X5cG4AGzG8WN8boJbWxW3tOvEgmrN2eG1ekE3KDGBAaO_KVd7QQ |
| ClassificationCodes | R979.1 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.14009/j.issn.1672-2124.2017.08.021 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Observation on Efficacy of Paclitaxel Combined with Oxaliplatin in Treatment of Advanced and Recurrent Cervical Cancer |
| DocumentTitle_FL | Observation on Efficacy of Paclitaxel Combined with Oxaliplatin in Treatment of Advanced and Recurrent Cervical Cancer |
| EndPage | 1062 |
| ExternalDocumentID | zgyyyypjyfx201708021 673182424 |
| GroupedDBID | 2RA 92L ALMA_UNASSIGNED_HOLDINGS CDYEO CQIGP W91 ~WA 2B. 4A8 92I 93N ABDBF ACUHS EOJEC OBODZ PSX TCJ TUS |
| ID | FETCH-LOGICAL-c641-e26fd04a8c413a23d8ceb25ad22e32482affe5403c1ad500e5a95bd6cf14fc163 |
| ISSN | 1672-2124 |
| IngestDate | Thu May 29 04:11:27 EDT 2025 Wed Feb 14 09:56:48 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Oxaliplatin Paclitaxel 奥沙利铂 效果 安全性 晚期与复发性宫颈癌 紫杉醇 Effects Safety Advanced and recurrent cervical cancer |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c641-e26fd04a8c413a23d8ceb25ad22e32482affe5403c1ad500e5a95bd6cf14fc163 |
| Notes | CHEN Fuchun1, ZHONG Li2 （ 1. Dept. of Gynecology, Longyan the First Hospital Affiliated to Fujian Medical University, Fujian Longyan 364000, China; 2. Dept. of Oncology, Longyan the Second Hospital, Fujian Longyan 364000, China） Paclitaxel ; Oxaliplatin ; Advanced and recurrent cervical, cancer; Effects ; Safety OBJECTIVE： To probe into the efficacy and safety of paclitaxel combined with oxaliplatin in treatment of advanced and recurrent cervical cancer. METHODS： 90 patients with advanced and recurrent cervical cancer admitted into Longyan the First Hospital Affiliated to Fujian Medical University from Feb. 2011 to Mar. 2012 were selected to be divided into observation group and control group via the random number table,with 45 cases in each.The control group was treated with paclitaxel combined with cisplatin,while the observation group received paclitaxel combined with oxaliplatin. The clinical efficacy,5-year survival and incidence of adverse drug reactions of two groups were observed. RESULTS： The total eff |
| PageCount | 2 |
| ParticipantIDs | wanfang_journals_zgyyyypjyfx201708021 chongqing_primary_673182424 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 中国医院用药评价与分析 |
| PublicationTitleAlternate | Evaluation and Analysis of Drug-use in Hospitals of China |
| PublicationTitle_FL | Evaluation and Analysis of Drug-Use in Hospitals of China |
| PublicationYear | 2017 |
| Publisher | 福建医科大学附属龙岩第一医院妇科,福建龙岩,364000%龙岩市第二医院肿瘤科,福建龙岩,364000 |
| Publisher_xml | – name: 福建医科大学附属龙岩第一医院妇科,福建龙岩,364000%龙岩市第二医院肿瘤科,福建龙岩,364000 |
| SSID | ssib025702234 ssib017477209 ssib001103637 ssib051368574 ssib000405437 ssib001215202 ssib036441963 ssib006563103 ssib057928707 |
| Score | 2.0887876 |
| Snippet | 目的：探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性。方法：选取2011年2月—2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90例,以随... R979.1; 目的:探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性.方法:选取2011年2月-2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 1061 |
| SubjectTerms | 奥沙利铂 安全性 效果 晚期与复发性宫颈癌 紫杉醇 |
| Title | 紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效观察 |
| URI | http://lib.cqvip.com/qk/86765X/201708/673182424.html https://d.wanfangdata.com.cn/periodical/zgyyyypjyfx201708021 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVCAB databaseName: Nutrition and Food Sciences Database issn: 1672-2124 databaseCode: DYU dateStart: 20150101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.cabidigitallibrary.org/product/zd omitProxy: true ssIdentifier: ssib001215202 providerName: CAB International – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate issn: 1672-2124 databaseCode: ABDBF dateStart: 20151101 customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn isFulltext: true dateEnd: 99991231 titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn omitProxy: true ssIdentifier: ssib057928707 providerName: EBSCOhost |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9RAFB_6AeJFFBVrtfTgnCQ1mUwmM8dkN0tR8NRCPS3ZfLR42FZtwfakRXQFP_GLLUpBLEUKCsWD4L9jdtv_wvcmaZqFUtRlCZOZye-9mUlmfi-ZeUPIFWlGrZaThIZlO6bBY3R5a4nIwI9MrisSGCK0t8-bYnqWX59z5oaGhyqzllaWW1PR2pHrSv6nVSEO2hVXyf5Dy5agEAFhaF84QgvD8a_amAYu9Tn1fBoIqupUKhooKgUFCz-QQBKp4jRwqDKplBjw9B8y-4wqhTEQ7-mrlE0lK5J8H5EVYLoaGVI9HahR1aABpz6ABxoQqGhd4zSosjCPNKnn6qRAK6aox7R0F3FkTQc8KvmgCK0J6AzXohpwOQAOzDks5HpanPKpn8utaW0VgoMgxIQK0VCgGIAgZkOL45jTdwf0B6FQXahAQFX55abAy7X2BBYOswCSc1WnMV0PGiTfmujgxUm-QrTo5YXLDBiz-cAw4FZud1np09ForvADOGVHjj3QGyo9-KCMqVIGTh90tZtYZh0OuuVUSOFCr4prdIbJKHOBLSGxvzVbodxAqisUEuiaLarnuDFxxYUb8HPcOu7gHAxOsJ8OXbThpoXACMs-2EY-rA5dsDkW7kignZeXJThB6EH5rh1XOnRPsrDYnr8DpEuvgWunYXu-QtdmTpNThZ016eUPzRkytLZwltzo_9jpfXq6__jJ3sO32atOtrXV2-1mna_7b9Z7u7_67z_0uhu9j5u_f77IvjzPXr7uPdjOvu3sf-70u8_6G48ww7vO3vZ69n3zHJlpBDO1aaPYTcSIBLeMhIk0NnkoI6BtIbNjGSUt5oQxYwkYFZKFaZqA-WJHVhg7ppk4oXJasYhSi6cRWC3nyUh7sZ1cIJMqjqQIE1tZieI8DaFzs2I7Dh2c9WAm4RgZL-uhuZQ7jWmW7TxGaFEzzaIruddcm1-F39Lt1fQ-1ieuf7cuHosyTk5izvxl4CUysnx3JbkM9Hi5NUFGPb_uNyb0ffQHmBWSOg |
| linkProvider | CAB International |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%B4%AB%E6%9D%89%E9%86%87%E8%81%94%E5%90%88%E5%A5%A5%E6%B2%99%E5%88%A9%E9%93%82%E6%B2%BB%E7%96%97%E6%99%9A%E6%9C%9F%E4%B8%8E%E5%A4%8D%E5%8F%91%E6%80%A7%E5%AE%AB%E9%A2%88%E7%99%8C%E7%9A%84%E7%96%97%E6%95%88%E8%A7%82%E5%AF%9F&rft.jtitle=%E4%B8%AD%E5%9B%BD%E5%8C%BB%E9%99%A2%E7%94%A8%E8%8D%AF%E8%AF%84%E4%BB%B7%E4%B8%8E%E5%88%86%E6%9E%90&rft.au=%E9%99%88%E7%A6%8F%E6%98%A5+%E9%92%9F%E8%8E%89&rft.date=2017&rft.issn=1672-2124&rft.volume=17&rft.issue=8&rft.spage=1061&rft.epage=1062&rft_id=info:doi/10.14009%2Fj.issn.1672-2124.2017.08.021&rft.externalDocID=673182424 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F86765X%2F86765X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgyyyypjyfx%2Fzgyyyypjyfx.jpg |